Role of transforming growth factor-β signaling in cancer

Journal of the National Cancer Institute

Volumn 92, Issue 17, 2000, Pages 1388-1402

  De Caestecker, Mark P ^a,b   Piek, Ester ^a,b   Roberts, Anita B ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034612789     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (221)

1. The hallmarks of cancer
2. Tissue structure, nuclear organization, and gene expression in normal and malignant breast
3. What might a stromal response mean to prostate cancer progression?
4. Effects of TGF-beta on the immune system: Implications for cancer immunotherapy
5. Tumor suppressor activity of the TGF-beta pathway in human cancers
6. TGF-beta and cancer
7. Genetic events and the role of TGF beta in epithelial tumour progression
8. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities
9. Control of junB and extracellular matrix protein expression by transforming growth factor-beta 1 is independent of simian virus 40 T antigen-sensitive growth-sensitive growth-inhibitory events
10. Regulation of transforming growth factor beta receptors in H-ras oncogene-transformed rat intestinal epithelial cells
11. Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene
12. The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms
13. TGF-beta signal transduction
14. Specificity, diversity, and regulation in TGF-beta superfamily signaling
15. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis
16. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
17. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
18. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
19. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas
20. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma
21. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor
22. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein
23. Mechanism of E1A-induced transforming growth factor-beta (TGF-beta) resistance in mouse keratinocytes involves repression of TGF-beta type II receptor transcription
24. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer
25. Relationships between chromatin organization and DNA methylation in determining gene expression
26. A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression
27. Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines
28. Human cut-like repressor protein binds TGFbeta type II receptor gene promoter
29. Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin
30. Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A
31. The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling
32. Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling
33. A novel protein distinguishes between quiescent and activated forms of the type I transforming growth factor beta receptor
34. The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response
35. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI
36. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts
37. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors
38. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor
39. Structural basis of Smad2 recognition by the Smad anchor for receptor activation
40. Controlling TGF-beta signaling
41. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
42. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling
43. TBRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling
44. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling
45. The TGF-beta family mediator Smad 1 is phosphorylated directly and activated functionally by the BMP receptor kinase
46. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response
47. Determinants of specificity in TGF-beta signal transduction
48. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12
49. Functions of mammalian Smad genes as revealed by targeted gene disruption in mice
50. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells
51. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells
52. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation
53. Ubiquitin-dependent degradation of TGF-beta-activated Smad2
54. Microtubule binding to Smads may regulate TGF beta activity
55. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
56. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways
57. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4
58. Smad8 mediates the signaling of the ALK-2 receptor serine kinase
59. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12
60. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2
61. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4
62. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes
63. Characterization of functional domains within Smad4/DPC4
64. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway
65. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells
66. Xenopus Smad4beta is the co-Smad component of developmentally regulated transcription factor complexes responsible for induction of early mesodermal genes
67. Smad6 inhibits signalling by the TGF-beta superfamily
68. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling
69. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling
70. Physical and functional interaction of murine and xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-beta receptors
71. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor
72. Vascular MADs: Two novel MAD-related genes selectively inducible by flow in human vascular endothelium
73. Transforming growth factor beta1 induces nuclear export of inhibitory smad7
74. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells
75. Regulation of Smad7 promoter by direct association with Smad3 and Smad4
76. Induction of Smad6 mRNA by bone morphogenetic proteins
77. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex
78. Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta 1 in COLO-357 cells
79. Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta 1
80. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members
81. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
82. Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta
83. Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation
84. Transforming growth factor (TGF)-beta stimulates hepatic jun-B and fos-B proto-oncogenes and decreases albumin mRNA
85. Transforming growth factor beta 1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation
86. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway
87. Inhibition of cell growth by TGF beta 1 is associated with inhibition of B-myb and cyclin A in both BALB/MK and Mv1Lu cells
88. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta
89. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer
90. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains
91. Regulation of c-fos gene induction and mitogenic effect of transforming growth factor-beta 1 in rat articular chondrocyte
92. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
93. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells
94. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15
95. TGF-beta-1 up-regulates cyclin D1 expression in COLO-357 cells, whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor
96. TGF-betal effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression
97. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B
98. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site
99. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members
100. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: Involvement of the small GTPase rhoA
101. Down-regulation of the cyclin A promoter by transforming growth factor-betal is associated with a reduction in phosphorylated activating transcription factor-1 and cyclic AMP-responsive element-binding protein
102. Human Smad3 and Smad4 are sequence-specific transcription activators
103. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: Involvement of Smad 3
104. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta
105. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene
106. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein
107. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter
108. Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic
109. Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-beta
110. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2
111. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3
112. A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3
113. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription
114. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene
115. Smad and AML proteins synergistically confer transforming growth factor betal responsiveness to human germ-line IgA genes
116. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-beta signaling
117. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling
118. Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif
119. A transcriptional partner for MAD proteins in TGF-beta signalling
120. Smad4 and FAST-1 in the assembly of activin-responsive factor
121. Smads bind directly to the Jun family of AP-1 transcription factors
122. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators
123. Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3
124. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes
125. A Smad transcriptional compressor
126. Multiple modes of repression by the Smad transcriptional corepressor TGIF
127. Transcriptional activating activity of Smad4: Roles of SMAD hetero-oligomerization and enhancement by an associating transactivator
128. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors
129. E1A inhibits transforming growth factor-beta signaling through binding to Smad proteins
130. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3
131. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells
132. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling
133. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling
134. c-Ski Acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads
135. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling
136. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein
137. A human Mad protein acting as a BMP-regulated transcriptional activator
138. Alteration of nucleosome structure as a mechanism of transcriptional regulation
139. Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein
140. Physical and functional interaction of SMADs and p300/CBP
141. Role of p300, a transcriptional coactivator, in signalling of TGF-beta
142. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300
143. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with co-activator p300/CREB-binding protein
144. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation
145. CREB binding protein is a required coactivator for Smad-dependent, transorming growth factor beta transcriptional responses in endothelial cells
146. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain
147. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling
148. Genetic and epigenetic contributions to colorectal cancer
149. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1
150. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras
151. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells
152. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases
153. MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells
154. Role of Ras and Mapks in TGFbeta signaling
155. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked
156. Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells
157. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription
158. Transforming growth factor-beta stimulates articular chondrocyte cell growth through p44/42 MAP kinase (ERK) activation
159. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling
160. TAB1: An activator of the TAK1 MAPKKK in TGF-beta signal transduction
161. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction
162. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression
163. Hematopoietic progenitor kinase 1 is a component of transforming growth factor beta-induced c-Jun N-terminal kinase signaling cascade
164. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway
165. Promoter sequences of the human transforming growth factor-β gene responsive to transforming growth factor-β1 autoinduction
166. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: Synergistic transcription factor interactions are targets for cancer therapy
167. Positive and negative modulation of vitamin D receptor function by transforming growth factor-beta signaling through smad proteins
168. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway
169. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA
170. Lessons from hereditary colorectal cancer
171. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas
172. Genetic approaches to the study of the molecular basis of human cancer
173. Genetic instability and darwinian selection in tumours
174. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers
175. A structural basis for mutational inactivation of the tumour suppressor Smad4
176. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
177. Cancer-susceptibility genes. Gatekeepers and caretakers
178. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice
179. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice
180. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation
181. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis
182. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
183. Frequent 4-bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients
184. DPC4 gene in various tumor types
185. Clinical and pathological associations with allelic loss in colorectal carcinoma
186. Allelic loss of chromosome 18q and prognosis in colorectal cancer
187. A novel tumor suppressor locus on chromosome 18q involved in the development of human lung cancer
188. DPC4/SMAD4 gene alterations in human cancer, and their functional implications
189. Evidence that loss of chromosome 18q is associated with tumor progression
190. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma
191. Mad-related genes in the human
192. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
193. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers
194. The DCC gene: Structural analysis and mutations in colorectal carcinomas
195. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene
196. Assignment1 of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization
197. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer
198. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
199. Mad-related genes in the human
200. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer
201. Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations
202. Allelotype of pancreatic adenocarcinoma using xenograft enrichment
203. A distinct tumor suppressor gene locus on chromosome 15q21.1 in sporadic form of colorectal cancer
204. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers
205. Screening SMAD1, SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis syndrome
206. SMAD genes in juvenile polyposis
207. Mutation analysis of the Smad3 gene in human ovarian cancers
208. Smad3 mutant mice develop metastatic colorectal cancer
209. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction
210. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta
211. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells
212. MDS1/EVI1 enhances TGF-beta 1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1
213. The cellular homologue of the transforming gene of SKV avian retrovirus maps to human chromosome region 1q22-q24
214. Establishment and characterization of a childhood pre-B acute lymphoblastic leukemia cell line, PER-278, with chromosome translocations t(1;19) and t(1;9)
215. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells
216. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration
217. Expression of TGF-beta related Smad proteins in human epithelial skin tumors
218. Expression of Smad proteins in human colorectal cancer
219. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer
220. Mutations in the tumour suppressors Smad2 and Smad4 inactivate TGF-beta signalling by targetting Smads to the ubiquitin proteasome pathway
221. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer